Literature DB >> 17845579

The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies.

L-P Boulet1, G Gauvreau, M-E Boulay, P O'Byrne, D W Cockcroft.   

Abstract

Allergen bronchoprovocation tests have been used for more than two decades in the investigation of respiratory allergic diseases such as asthma and rhinitis. These bronchial challenges are now well standardized and can offer key information on the therapeutic potential of new agents and on their anti-inflammatory effects on the airways. Both standard and low-dose allergen provocations are safe when performed by experienced investigators and do not lead to persistent worsening of asthma or change in airway function. The evaluation of new therapeutic agents by these methods can also provide important information on the mechanisms of development and persistence of airway diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845579     DOI: 10.1111/j.1398-9995.2007.01499.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  16 in total

1.  Allergen-induced asthma.

Authors:  Donald W Cockcroft
Journal:  Can Respir J       Date:  2014-05-02       Impact factor: 2.409

Review 2.  The pharmacological modulation of allergen-induced asthma.

Authors:  L L Ma; Paul M O'Byrne
Journal:  Inflammopharmacology       Date:  2012-10-25       Impact factor: 4.473

3.  Intranasal challenge with increasing ovalbumin doses differently affects airway hyperresponsiveness and inflammatory cell accumulation in mouse model of asthma.

Authors:  Berislav Bosnjak; Vanesa Ivetić Tkalcević; Koraljka Durić; Daniela Belamarić; Snjezana Cuzić; Zeljko Ferencić; Karmen Brajsa; Ines Glojnarić; Roberto Antolović; Boska Hrvacić
Journal:  Inflamm Res       Date:  2009-05-08       Impact factor: 4.575

4.  Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma.

Authors:  Louis-Philippe Boulet; Gail M Gauvreau; Donald W Cockcroft; Beth Davis; Luc Vachon; Yvon Cormier; Paul M O'Byrne
Journal:  Can Respir J       Date:  2015 Jul-Aug       Impact factor: 2.409

5.  Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity.

Authors:  Seyed Mohammadreza Bolandi; Zohreh Abdolmaleki; Mohammad-Ali Assarehzadegan
Journal:  Inflammopharmacology       Date:  2021-03-19       Impact factor: 4.473

6.  Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.

Authors:  Gail M Gauvreau; Louis-Philippe Boulet; Christine Schmid-Wirlitsch; Johanne Côté; Mylinh Duong; Kieran J Killian; Joanne Milot; Francine Deschesnes; Tara Strinich; Richard M Watson; Dirk Bredenbröker; Paul M O'Byrne
Journal:  Respir Res       Date:  2011-10-26

7.  Comparing the effects of two inhaled glucocorticoids on allergen-induced bronchoconstriction and markers of systemic effects, a randomised cross-over double-blind study.

Authors:  Jan Lötvall; Mona Palmqvist; Peter Arvidsson
Journal:  Clin Transl Allergy       Date:  2011-10-31       Impact factor: 5.871

8.  Development of asthmatic response upon bronchial allergen challenge is associated with dynamic changes of interleukin-10-producing and interleukin-10-responding CD4+ T cells.

Authors:  Marcin Moniuszko; Kamil Grubczak; Krzysztof Kowal; Andrzej Eljaszewicz; Malgorzata Rusak; Marta Jeznach; Ewa Jablonska; Milena Dabrowska; Anna Bodzenta-Lukaszyk
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

9.  Airway responses and inflammation in subjects with asthma after four days of repeated high-single-dose allergen challenge.

Authors:  Johannes Schulze; Sandra Voss; Ulrich Zissler; Markus A Rose; Stefan Zielen; Ralf Schubert
Journal:  Respir Res       Date:  2012-09-19

10.  CD4⁺ and CD8⁺ T cells play a central role in a HDM driven model of allergic asthma.

Authors:  Kristof Raemdonck; Katie Baker; Nicole Dale; Eric Dubuis; Fisnik Shala; Maria G Belvisi; Mark A Birrell
Journal:  Respir Res       Date:  2016-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.